Share “News Summary: Charges help cut Merck Q4...”

News Summary: Charges help cut Merck Q4 profit

Published on NewsOK Modified: February 1, 2013 at 4:46 pm •  Published: February 1, 2013
Advertisement

PROFIT DROP: Lower sales due to generic competition and one-time charges cut Merck & Co.'s fourth-quarter profit by 7 percent, to $1.4 billion, or 46 cents per share. Sales were down 5 percent, at $11.74 billion.

UNEXPECTED DELAY: Merck said it's reviewing safety and efficacy data from a crucial late-stage patient test of its experimental osteoporosis drug. It will hold off from applying for approval of the drug, odanacatib, until 2014. It had originally planned file in the first half of this year.

FINANCIAL FORECAST: Merck expects 2013 earnings per share of $3.60 to $3.70, excluding charges, and revenue around $47 billion.


AROUND THE WEB

  1. 1
    Oklahoma officials investigating dog-skinning case
  2. 2
    Man charged with raping, beating ex-girlfriend is named Tulsa's Most Wanted fugitive
  3. 3
    Former caregiver for foster families arrested on child porn complaints
  4. 4
    Sister Helen Prejean appeals to governor to stay convicted killer Richard Glossip's execution
  5. 5
    Son and five others indicted on murder charges in Pryor woman's overdose death
+ show more

FEATURED JOBS



× Trending business Article